The growing popularity of GLP-1 weight-loss therapies is quietly changing patterns in the U.S. cannabis market, which industry observers value at about $40 billion. Retailers and users report altered demand and questions about how the drugs modify cannabis experiences, particularly appetite-related effects commonly called "munchies."
Online forum accounts from patients on GLP-1 medications frequently describe diminished cravings and uncertainty about marijuana's aftereffects. Dispensing businesses say these anecdotal reports are reshaping how they counsel customers.
In New York City's Flatiron neighborhood, Stoops NYC has begun recommending lower-dose edibles, vapes and tinctures more often to patrons who indicate they are taking GLP-1 drugs. The concern centers on digestion - GLP-1 therapies slow gastric emptying, which can postpone the onset of effects from edible cannabis. Retailers fear that delay could prompt some consumers to ingest additional doses too soon and experience unexpectedly strong highs.
"As (GLP) adoption accelerates, we are exploring ways to provide clearer guidance at the point of sale," said Wendy Bronfein, co-founder and chief brand officer at Curio Wellness.
Although definitive scientific evidence is still limited, researchers have begun to probe the connection more directly. This year, the National Institute on Drug Abuse is sponsoring a clinical trial testing tirzepatide - the active ingredient in Eli Lilly's weight-loss drugs - as a potential treatment for cannabis use disorder. The institute's director, Dr. Nora Volkow, said retrospective analyses of electronic health records showed that patients with diabetes prescribed GLP-1 agents such as semaglutide had significantly better outcomes related to cannabis use disorder compared with patients on other diabetes treatments.
Another clinical trial, led by Brigham and Women's Hospital, is expected to begin later this year.
Shifts in consumer behavior extend beyond dosing. Some GLP-1 users appear to be substituting cannabis for alcohol, while others are adopting more targeted usage - for example, consuming cannabis intentionally for sleep or stress relief rather than more casual consumption, according to Steph Woods, vice president of sales at SōRSE Technology.
Data from the cannabis education nonprofit Realm of Caring indicates rising consumer curiosity about the intersection of cannabis and metabolism. Since 2024, its hotline's top 20 queries have included phrases such as "THC for weight loss," "weed strains that suppress appetite," and "edibles that don’t make you hungry."
Industry experts caution against treating current accounts as conclusive. Much of the evidence remains anecdotal and subject to individual variation. "There is no one plus one equals two scenario here," said Michael Flemmens, executive vice president of research at SōRSE Technology. He noted that metabolism, dosage, tolerance and the specific GLP-1 agent used could all influence outcomes.
Alongside these market and behavioral notes, promotional material present in the original reporting references tools that evaluate pharmaceutical equities. One such tool, ProPicks AI, claims to assess companies including Eli Lilly on more than 100 financial metrics and highlights historical stock picks; the cited examples include Super Micro Computer and AppLovin with noted past returns. The promotional text also included a brief callout about a price-related sales event.
For retailers, researchers and investors, the unfolding interaction between GLP-1 therapies and cannabis use raises questions about product assortment, point-of-sale guidance and clinical pathways. Current retail responses emphasize lower-dose and more controllable formats, while clinical work aims to move beyond anecdote to evidence.
Key takeaways
- Retailers in the U.S. cannabis market are adjusting product recommendations - favoring lower-dose edibles, vapes and tinctures - for customers on GLP-1 weight-loss drugs due to reported appetite changes and altered onset of edible effects.
- Researchers and federal agencies are initiating clinical trials to study whether GLP-1 agents like tirzepatide have therapeutic or interaction effects related to cannabis use disorder, and retrospective analyses have suggested improved outcomes for some patients on GLP-1 drugs compared with other diabetes treatments.
- Consumer interest is shifting toward targeted cannabis use and questions about metabolism, with educational hotlines reporting appetite-related queries as among the most common since 2024.
Risks and uncertainties
- Scientific evidence connecting GLP-1 therapies and changes in cannabis effects is limited and largely anecdotal, creating uncertainty for retailers, clinicians and consumers - impacting the cannabis retail and healthcare sectors.
- Variability in individual responses - due to metabolism, dosage, tolerance and the specific GLP-1 medication - complicates clear, universal point-of-sale guidance and could raise liability or consumer-safety questions for dispensaries.
- Ongoing clinical trials may alter prevailing assumptions; current retail adjustments are precautionary and could change as rigorous trial results become available, affecting market strategy for cannabis producers and retailers.